Survival of metastatic cancer and myeloma patients after diagnosis of Osteonecrosis of Jaws (ONJ). Potential impact on ONJ treatment strategies.

2021 · doi:10.32388/ikliwh
preprint OA: closed
Full text JSON View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-17 ⓘ

This study analyzed survival data for 609 metastatic cancer and myeloma patients after ONJ diagnosis, finding median survivals ranging from 11 to 53 months, suggesting surgery exclusion is not universally warranted.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Survival of cancer and myeloma patients after diagnosis of medication-related Osteonecrosis of Jaws (ONJ) has not adequately been reported. ONJ is not rare in patients with bone metastatic cancer and myeloma patients, occurring mostly after prolonged treatment with antiresorptive drugs (zoledronic acid and other bisphosphonates, and/or denosumab). On the other hand, expected residual survival can influence the choice of ONJ treatment strategies (surgical versus conservative). We reviewed survival data after ONJ diagnosis time of 609 patients registered in the regional database of a cancer network in North-Western Italy (Rete Oncologica di Piemonte e Valle d’Aosta).  Main characteristics. Disease:  metastatic breast cancer 43%; myeloma 24.1%; prostate cancer 19.2%; lung cancer 5.7.% renal cancer 3.2% other cancer types 4.8%. Sex: 237 M, 372 F. Median age 69 (32-90) years. Main treatment: 79.1% zoledronic acid, 4.8% denosumab; 16.1 % other drugs or drug sequences.  Observed actuarial median survival after the registered ONJ diagnosis time was 29 (95% CI 26-35) months for breast cancer patients, 31 (95% CI 28-43) months for myeloma patients, 19 (95% CI 15-26) months for prostate cancer patients, 11 (95% CI 5-19) months for lung cancer patients, 30 (95% CI 13-57) months for renal cancer patients, 53 (95% CI 17-84) months for other cancer patients.  Two, three and four-year actuarial survival were respectively: 57.6%, 42.2%, 33.9% for breast cancer patients, 64.6%, 44.9%, 36% for myeloma patients, 42.7%, 27.3%, 19.6% for prostate patients; 28.5%, 14.3%, 11.4% for lung cancer patients; 57.8%, 36.8%, 26.3% for renal cancer patients; 62%, 58.6%, 58.6% for others cancer types.  In conclusion, expected survival after ONJ diagnosis is not really short (less than one year) in most of ONJ patients. Our data do not support generalized exclusion of jawbone surgery in ONJ patients due to expected short survival.
Full text 621 characters · extracted from oa-doi-fallback · click to expand
There is a newer version available for this {{ publicationType }}. View latest version {{ publication.field_name }} {{ publication.subfield_name }} Copyright: © {{ publicationYear }} {{ publication.presentation_authors[0].full_name + (publication.presentation_authors.length > 1 ? ' et al' : '') }}. This is an open access publication distributed under the terms of the CC BY 4.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Check the {{ publicationType | capitalize }} Source for copyright and license information. Listen on

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-05-19T01:45:01.086888+00:00